secwatch / observer

8-K filed January 8, 2026, 6:59 PM ET ticker JSPR CIK 0001788028

other material confidence high sentiment positive materiality 0.70

Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b

Jasper Therapeutics, Inc.

67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.
Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.
Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.
Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-002329
form_type: 8-K
ticker: JSPR
cik: 0001788028
company_name: Jasper Therapeutics, Inc.
filed_at: 2026-01-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.185780+00:00
generated_at: 2026-05-16T11:14:28.736257+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-002329
json_url: https://secwatch.observer/filing/0001213900-26-002329.json
markdown_url: https://secwatch.observer/filing/0001213900-26-002329.md
text_url: https://secwatch.observer/filing/0001213900-26-002329.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/0001213900-26-002329-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/ea0272248-8k_jasper.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

PECE

Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M

Peace Acquisition Corp. June 1, 2026, 5:16 PM ET other_material Items 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MUX

McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M

McEwen Inc. June 1, 2026, 5:14 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-002329

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.